Document is current
Any future updates will be listed below
-
Authors
Gustav, Marco https://orcid.org/0009-0009-3598-5720
Reitsam, Nic Gabriel https://orcid.org/0000-0002-0070-3158
Carrero, Zunamys I. https://orcid.org/0000-0001-8501-1566
Loeffler, Chiara M. L. https://orcid.org/0009-0002-9659-5194
van Treeck, Marko
Yuan, Tanwei https://orcid.org/0000-0001-7387-6327
West, Nicholas P.
Quirke, Philip https://orcid.org/0000-0002-3597-5444
Brinker, Titus J. https://orcid.org/0000-0002-3620-5919
Brenner, Hermann
Favre, Loëtitia
Märkl, Bruno
Stenzinger, Albrecht https://orcid.org/0000-0003-1001-103X
Brobeil, Alexander
Hoffmeister, Michael https://orcid.org/0000-0002-8307-3197
Calderaro, Julien
Pujals, Anaïs https://orcid.org/0000-0002-3452-7420
Kather, Jakob Nikolas
- License Information
-
More Information
Article History
Received: 7 November 2023
Accepted: 14 April 2024
First Online: 23 May 2024
Competing interests
: J.N.K. declares consulting services for Owkin, France; DoMore Diagnostics, Norway; AstraZeneca, UK and Panakeia, UK and has received honoraria for lectures by Eisai, Roche, MSD, and Fresenius. J.N.K. is Deputy Editor at “npj Precision Oncology”. M.G. has received honoraria from Techniker Krankenkasse. P.Q. declares research funding from Roche and honoraria for lectures by Roche, Bayer, Amgen. B.M. has received honoraria from Merck, Roche, MSD, BMS, and Bayer. A.P. declares consulting services for AstraZeneca, Biocartis and declares research funding from Bayer. No other potential conflicts of interest are reported by any of the authors.
